Medican Enterprises Inc (OTCMKTS:MDCN) has been fluctuating quite a lot in the market recently. The company had recently announced the expansion of its real estate business, with a deal with BRCOG. The real estate deal was also targeted at the marijuana industry, a prospect that MDCN has been leaning towards. However, the news made no change to the stock as it continued to fall. The only thing that has helped the stock in the past month is Medican’s acquisition of TWYN, a branding company for the marijuana industry.
Medican’s attempts to move the stock up with positive developments has been facing quite a lot of problems, since the company hosts a poor balance sheet, with almost no revenues. TWYN is, however, expected to change that for the company, as analysts believe that the new subsidiary would add $400,000 to annual revenues of its parent. Unfortunately, to gain these revenues Medican had to look towards dilution of $1 million worth of stock.
BRCOG would also be paying Medican $9,000 a month, as per the lease agreements, but it still makes the investors wonder if it is enough. Although MDCN is based in one of the most profitable markets in the US, it still has not been reflected on the company’s finances. Medican focuses on development, distribution and marketing of medical grade cannabis to the global market. Currently, the medical marijuana market is valued at $2.34 billion and is expected to reach $35 billion by 2020. Unfortunately, Medican has not been reaping the benefits.
Medican’s real estate business to lease properties for growing medical marijuana to licensed growers, seems to be the only profitable area of the company. It is pretty clear that the company is not able to take care of all areas of its business and needs to become increasingly focused on just branding and leasing, if it wants to become profitable.
Medican Enterprises Inc (OTCMKTS:MDCN) reported no change in the May 28th session, despite trading 44.71 million shares and closed at $0.0022.
